These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22316604)

  • 1. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration.
    Schulte A; Günther HS; Martens T; Zapf S; Riethdorf S; Wülfing C; Stoupiec M; Westphal M; Lamszus K
    Clin Cancer Res; 2012 Apr; 18(7):1901-13. PubMed ID: 22316604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme.
    Stockhausen MT; Broholm H; Villingshøj M; Kirchhoff M; Gerdes T; Kristoffersen K; Kosteljanetz M; Spang-Thomsen M; Poulsen HS
    Exp Cell Res; 2011 Jul; 317(11):1513-26. PubMed ID: 21514294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR.
    Pandita A; Aldape KD; Zadeh G; Guha A; James CD
    Genes Chromosomes Cancer; 2004 Jan; 39(1):29-36. PubMed ID: 14603439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
    Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
    Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2.
    Martens T; Laabs Y; Günther HS; Kemming D; Zhu Z; Witte L; Hagel C; Westphal M; Lamszus K
    Clin Cancer Res; 2008 Sep; 14(17):5447-58. PubMed ID: 18765536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
    Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential role of EGF and BFGF in human GBM-TIC proliferation: relationship to EGFR-tyrosine kinase inhibitor sensibility.
    Bajetto A; Porcile C; Pattarozzi A; Scotti L; Aceto A; Daga A; Barbieri F; Florio T
    J Biol Regul Homeost Agents; 2013; 27(1):143-54. PubMed ID: 23489694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of cytoplasmic-domain substituted epidermal growth factor receptor inhibits tumorigenicity of EGFR-overexpressed human glioblastoma multiforme.
    Liu KJ; Chen CT; Hu WS; Hung YM; Hsu CY; Chuang BF; Juang SH
    Int J Oncol; 2004 Mar; 24(3):581-90. PubMed ID: 14767543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts.
    Bigner SH; Humphrey PA; Wong AJ; Vogelstein B; Mark J; Friedman HS; Bigner DD
    Cancer Res; 1990 Dec; 50(24):8017-22. PubMed ID: 2253244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.
    Sarkaria JN; Carlson BL; Schroeder MA; Grogan P; Brown PD; Giannini C; Ballman KV; Kitange GJ; Guha A; Pandita A; James CD
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2264-71. PubMed ID: 16609043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGF-effects in vitro and in vivo on a carcinoma cell line rich in EGFR.
    Torp SH; Helseth E; Unsgaard G; Dalen A
    Anticancer Res; 1995; 15(3):667-70. PubMed ID: 7645940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The MET oncogene is a functional marker of a glioblastoma stem cell subtype.
    De Bacco F; Casanova E; Medico E; Pellegatta S; Orzan F; Albano R; Luraghi P; Reato G; D'Ambrosio A; Porrati P; Patanè M; Maderna E; Pollo B; Comoglio PM; Finocchiaro G; Boccaccio C
    Cancer Res; 2012 Sep; 72(17):4537-50. PubMed ID: 22738909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
    Bax DA; Gaspar N; Little SE; Marshall L; Perryman L; Regairaz M; Viana-Pereira M; Vuononvirta R; Sharp SY; Reis-Filho JS; Stávale JN; Al-Sarraj S; Reis RM; Vassal G; Pearson AD; Hargrave D; Ellison DW; Workman P; Jones C
    Clin Cancer Res; 2009 Sep; 15(18):5753-61. PubMed ID: 19737945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of two distinct epithelial cell lines from a single feline mammary carcinoma with different tumorigenic potential in nude mice and expressing different levels of epidermal growth factor receptors.
    Minke JM; Schuuring E; van den Berghe R; Stolwijk JA; Boonstra J; Cornelisse C; Hilkens J; Misdorp W
    Cancer Res; 1991 Aug; 51(15):4028-37. PubMed ID: 1649697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplification of the EGFR gene can be maintained and modulated by variation of EGF concentrations in in vitro models of glioblastoma multiforme.
    William D; Mokri P; Lamp N; Linnebacher M; Classen CF; Erbersdobler A; Schneider B
    PLoS One; 2017; 12(9):e0185208. PubMed ID: 28934307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
    Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
    Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The deletion mutant EGFRvIII significantly contributes to stress resistance typical for the tumour microenvironment.
    Theys J; Jutten B; Dubois L; Rouschop KM; Chiu RK; Li Y; Paesmans K; Lambin P; Lammering G; Wouters BG
    Radiother Oncol; 2009 Sep; 92(3):399-404. PubMed ID: 19616331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines.
    Carrasco-García E; Saceda M; Grasso S; Rocamora-Reverte L; Conde M; Gómez-Martínez A; García-Morales P; Ferragut JA; Martínez-Lacaci I
    Exp Cell Res; 2011 Jun; 317(10):1476-89. PubMed ID: 21439954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A distinct subset of glioma cell lines with stem cell-like properties reflects the transcriptional phenotype of glioblastomas and overexpresses CXCR4 as therapeutic target.
    Schulte A; Günther HS; Phillips HS; Kemming D; Martens T; Kharbanda S; Soriano RH; Modrusan Z; Zapf S; Westphal M; Lamszus K
    Glia; 2011 Apr; 59(4):590-602. PubMed ID: 21294158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.